Dechra Pharmaceuticals (DPH)

Sector:

Pharma and Biotech

Index:

FTSE 100

4,194.00p
   
  • Change Today:
      68.00p
  • 52 Week High: 5,405.00
  • 52 Week Low: 3,272.00
  • Currency: UK Pounds
  • Shares Issued: 108.36m
  • Volume: 110,545
  • Market Cap: £4,544.82m
  • RiskGrade: 121
  • Beta: 0.03

DPH Overview

Dechra Pharmaceuticals, founded in 1997 following a management buy-out from Lloyds Chemists, develops prescription only veterinary medicines for dogs, cats and horses. Most of its projects involve adapting treatments, currently used by humans, for the animal market. Expertise is in the development, manufacturing and sales and marketing of high quality products exclusively for veterinarians worldwide. It listed in London in 2000.
Registrars: Computershare Investor Services PLC

Key Personnel

Independent Non-Executive Director: Julian Heslop
CEO: Ian Page
CFO: Paul Sandland
Independent Non-Executive Director: Lawson Macartney
Independent Non-Executive Director: Lisa Bright
Managing Director: Tony Griffin
Non-Executive Chairman: Alison Platt
Senior Independent Non-Executive Director: Ishbel Jean Stewart Macpherson
Non-Executive Dir:

Contact Details

Address: 24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, United Kingdom, CW9 7UA
Phone: +44 (0) 160 681 4730
Fax: +44 (0) 160 681 4731
Website: http://www.dechraplc.com/

Listings

Sector: Pharma and Biotech(LSE)
Index: FTSE 100FTSE 350FTSE All-Share
Overseas Listings: BATSLON:DPHL
ISIN: GB0009633180

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

DPH Market Data

Currency UK Pounds
Share Price 4,194.00p
Change Today 68.00p
% Change 1.65 %
52 Week High 5,405.00
52 Week Low 3,272.00
Volume 110,545
Shares Issued 108.36m
Market Cap £4,544.82m
Beta 0.03
RiskGrade 121

DPH Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
99.1% below the market average99.1% below the market average99.1% below the market average99.1% below the market average99.1% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Price Trend
17.58% above the market average17.58% above the market average17.58% above the market average17.58% above the market average17.58% above the market average
23.81% above the sector average23.81% above the sector average23.81% above the sector average23.81% above the sector average23.81% above the sector average
Income
85.87% below the market average85.87% below the market average85.87% below the market average85.87% below the market average85.87% below the market average
60% below the sector average60% below the sector average60% below the sector average60% below the sector average60% below the sector average
Growth
82.67% above the market average82.67% above the market average82.67% above the market average82.67% above the market average82.67% above the market average
48.57% above the sector average48.57% above the sector average48.57% above the sector average48.57% above the sector average48.57% above the sector average

What The Brokers Say

Strong Buy 4
Buy 0
Neutral 5
Sell 0
Strong Sell 1
Total 10
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

DPH Dividends

  Latest Previous
  Final Interim
Ex-Div 28-Oct-21 04-Mar-21
Paid 19-Nov-21 07-Apr-21
Amount 29.39p 11.11p

Trades for 20-Jan-2022

Time Volume / Share Price
16:15 65 @ 4,194.00p
16:15 11 @ 4,194.00p
16:14 123 @ 4,196.00p
16:14 87 @ 4,196.00p
16:14 57 @ 4,196.00p

DPH Key Personnel

CEO Ian Page
CFO Paul Sandland

Top of Page